Philips launches a fixed-configuration version of its HyperVue coronary system in the United States
In a press release published on October 30, 2026, Royal Philips announced the commercial availability in the United States of the HyperVue Integrated System, which combines coronary imaging and physiology measurement in the catheterization lab. The stated objective is to keep these tools connected and immediately accessible during coronary angioplasty procedures.
Coronary imaging and physiology combined on a fixed platform
The HyperVue Integrated System is a permanently installed configuration in a dedicated catheterization lab. It combines DeepOCT+NIRS intravascular imaging and X1-FFR physiological assessment, a coronary measurement derived from angiography and performed without medication.
The mobile version of the HyperVue system, by contrast, must be brought into the room, powered, and connected for each procedure. By eliminating these steps, the fixed configuration is designed to reduce preparation time and make advanced imaging and physiology more accessible on a daily basis in the catheterization lab.
A touchscreen mounted on the table allows the system to be operated at the patient's bedside, within the sterile field. The new configuration also introduces controller updates intended to simplify installation and use.
X1-FFR is an FDA-authorized platform based on artificial intelligence. According to Philips, it is the only angiography-derived FFR solution authorized by the U.S. agency that requires only a single angiographic view, instead of two or three, to provide an FFR value.
A launch integrated into the group's coronary guidance portfolio
The new system complements the group's coronary guidance offering, alongside its intravascular ultrasound (IVUS) and physiology solutions. At the TCT 2026 conference, held in San Diego from October 31 to November 3, Philips will present it together with IntraSight Plus, its interventional guidance platform available in the United States.
The latter combines IVUS, iFR/FFR physiology, co-registration, tri-registration, and real-time device visualization. “For advanced intravascular imaging to become part of everyday practice, it must integrate naturally with the high-volume activity of the interventional room,” said Stacy Beske, head of the Image-Guided Therapy Devices business at Philips.
Richard Shlofmitz, Chief of Cardiology at St. Francis Hospital & Heart Center (Catholic Health), for his part stated that he wishes to continue his collaboration with Philips to explore how a more integrated organization can support effective, patient-centered care.
